Epigenetics in Acute Myeloid Leukemia

Seminars in Oncology

Volumn 35, Issue 4, 2008, Pages 378-387

  Plass, Christoph ^a   Oakes, Christopher ^a   Blum, William ^b   Marcucci, Guido ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMATIN; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DNA TRANSCRIPTION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENOME; HEMATOPOIESIS; HUMAN; PRIORITY JOURNAL; TISSUE SPECIFICITY;

CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIUM; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HISTONE DEACETYLASES; HISTONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; RNA, UNTRANSLATED;

EID: 48749122610     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.04.008     Document Type: Article

References (99)

1. Mrozek K., Heerema N.A., and Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 18 (2004) 115-136
2. Caligiuri M.A., Strout M.P., Lawrence D., Arthur D.C., Baer M.R., Yu F., et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58 (1998) 55-59
3. Gilliland D.G., and Griffin J.D. Role of FLT3 in leukemia. Curr Opin Hematol 9 (2002) 274-281
4. Dohner K., Schlenk R.F., Habdank M., Scholl C., Rucker F.G., Corbacioglu A., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106 (2005) 3740-3746
5. Baldus C.D., Liyanarachchi S., Mrozek K., Auer H., Tanner S.M., Guimond M., et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci U S A 101 (2004) 3915-3920
6. Heuser M., Beutel G., Krauter J., Dohner K., von Neuhoff N., Schlegelberger B., et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108 (2006) 3898-3905
7. Baldus C.D., Tanner S.M., Ruppert A.S., Whitman S.P., Archer K.J., Marcucci G., et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 102 (2003) 1613-1618
8. Chong S., and Whitelaw E. Epigenetic germline inheritance. Curr Opin Genet Dev 14 (2004) 692-696
9. Li E., Bestor T.H., and Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69 (1992) 915-926
10. Okano M., Bell D.W., Haber D.A., and Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 (1999) 247-257
11. Hansen R.S., Wijmenga C., Luo P., Stanek A.M., Canfield T.K., Weemaes C.M., et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A 96 (1999) 14412-14417
12. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., and Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23 (1999) 185-188
13. Morgan H.D., Santos F., Green K., Dean W., and Reik W. Epigenetic reprogramming in mammals. Hum Mol Genet 14 (2005) R47-R58
14. Barreto G., Schafer A., Marhold J., Stach D., Swaminathan S.K., Handa V., et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 445 (2007) 671-675
15. Jost J.P., Oakeley E.J., Zhu B., Benjamin D., Thiry S., Siegmann M., et al. 5-Methylcytosine DNA glycosylase participates in the genome-wide loss of DNA methylation occurring during mouse myoblast differentiation. Nucleic Acids Res 29 (2001) 4452-4461
16. Hoffmann M.J., and Schulz W.A. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 83 (2005) 296-321
17. Bestor T.H., and Tycko B. Creation of genomic methylation patterns. Nat Genet 12 (1996) 363-367
18. Recillas-Targa F., De La Rosa-Velazquez I.A., Soto-Reyes E., and Benitez-Bribiesca L. Epigenetic boundaries of tumour suppressor gene promoters: the CTCF connection and its role in carcinogenesis. J Cell Mol Med 10 (2006) 554-568
19. Klose R.J., and Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31 (2006) 89-97
20. Kouzarides T. Chromatin modifications and their function. Cell 128 (2007) 693-705
21. Valencia-Sanchez M.A., Liu J., Hannon G.J., and Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20 (2006) 515-524
22. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104 (2007) 15805-15810
23. Bayne E.H., and Allshire R.C. RNA-directed transcriptional gene silencing in mammals. Trends Genet 21 (2005) 370-373
24. Heard E., and Disteche C.M. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev 20 (2006) 1848-1867
25. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., and Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24 (2000) 88-91
26. Rountree M.R., Bachman K.E., and Baylin S.B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25 (2000) 269-277
27. D'Alessio A.C., and Szyf M. Epigenetic tete-a-tete: the bilateral relationship between chromatin modifications and DNA methylation. Biochem Cell Biol 84 (2006) 463-476
28. Fuks F., Hurd P.J., Deplus R., and Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 31 (2003) 2305-2312
29. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006) 871-874
30. Lehnertz B., Ueda Y., Derijck A.A., Braunschweig U., Perez-Burgos L., Kubicek S., et al. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol 13 (2003) 1192-1200
31. Gibbons R.J., McDowell T.L., Raman S., O'Rourke D.M., Garrick D., Ayyub H., et al. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat Genet 24 (2000) 368-371
32. Dennis K., Fan T., Geiman T., Yan Q., and Muegge K. Lsh, a member of the SNF2 family, is required for genome-wide methylation. Genes Dev 15 (2001) 2940-2944
33. Zhu H., Geiman T.M., Xi S., Jiang Q., Schmidtmann A., Chen T., et al. Lsh is involved in de novo methylation of DNA. EMBO J 25 (2006) 335-345
34. Ooi S.K., Qiu C., Bernstein E., Li K., Jia D., Yang Z., et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448 (2007) 714-717
35. Jia D., Jurkowska R.Z., Zhang X., Jeltsch A., and Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 449 (2007) 248-251
36. D'Alessio A.C., Weaver I.C., and Szyf M. Acetylation-induced transcription is required for active DNA demethylation in methylation-silenced genes. Mol Cell Biol 27 (2007) 7462-7474
37. Workman J.L. Nucleosome displacement in transcription. Genes Dev 20 (2006) 2009-2017
38. Oakes C.C., Smiraglia D.J., Plass C., Trasler J.M., and Robaire B. Aging results in hypermethylation of ribosomal DNA in sperm and liver of male rats. Proc Natl Acad Sci U S A 100 (2003) 1775-1780
39. Eckhardt F., Lewin J., Cortese R., Rakyan V.K., Attwood J., Burger M., et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38 (2006) 1378-1385
40. Robertson K. DNA methylation and human disease. Nat Rev Genet 6 (2005) 597-610
41. Spivakov M., and Fisher A.G. Epigenetic signatures of stem-cell identity. Nat Rev Genet 8 (2007) 263-271
42. Song F., Smith J.F., Kimura M.T., Morrow A.D., Matsuyama T., Nagase H., et al. Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression. Proc Natl Acad Sci U S A 102 (2005) 3336-3341
43. Klose R.J., Sarraf S.A., Schmiedeberg L., McDermott S.M., Stancheva I., and Bird A.P. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 19 (2005) 667-678
44. Stratling W.H., and Yu F. Origin and roles of nuclear matrix proteins. Specific functions of the MAR-binding protein MeCP2/ARBP. Crit Rev Eukaryot Gene Expr 9 (1999) 311-318
45. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 310 (2006) 251-274
46. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24 (2000) 132-138
47. Smith L.T., Otterson G.A., and Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet 23 (2007) 449-456
48. Baylin S.B., Fearon E.R., Vogelstein B., de Bustros A., Sharkis S.J., Burke P.J., et al. Hypermethylation of the 5′ region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 70 (1987) 412-417
49. Pfeifer G.P., Steigerwald S., Boehm T.L., and Drahovsky D. DNA methylation levels in acute human leukemia. Cancer Lett 39 (1988) 185-192
50. Costello J.F., and Plass C. Methylation matters. J Med Genet 38 (2001) 285-303
51. Issa J.P., Zehnbauer B.A., Civin C.I., Collector M.I., Sharkis S.J., Davidson N.E., et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 56 (1996) 973-977
52. Herman J.G., Civin C.I., Issa J.P., Collector M.I., Sharkis S.J., and Baylin S.B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57 (1997) 837-841
53. Voso M.T., Scardocci A., Guidi F., Zini G., Di Mario A., Pagano L., et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103 (2004) 698-700
54. Seedhouse C.H., Das-Gupta E.P., and Russell N.H. Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia 17 (2003) 83-88
55. Melki J.R., Vincent P.C., Brown R.D., and Clark S.J. Hypermethylation of E-cadherin in leukemia. Blood 95 (2000) 3208-3213
56. Issa J.P., Zehnbauer B.A., Kaufmann S.H., Biel M.A., and Baylin S.B. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 57 (1997) 1678-1681
57. Plass C., Yu F., Yu L., Strout M.P., El-Rifai W., Elonen E., et al. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene 18 (1999) 3159-3165
58. Agrawal S., Hofmann W.K., Tidow N., Ehrich M., van den Boom D., Koschmieder S., et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 109 (2007) 3895-3905
59. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109 (2003) 80-88
60. Melki J.R., Vincent P.C., and Clark S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59 (1999) 3730-3740
61. Toyota M., Kopecky K.J., Toyota M.O., Jair K.W., Willman C.L., and Issa J.P. Methylation profiling in acute myeloid leukemia. Blood 97 (2001) 2823-2829
62. Rush L.J., Dai Z., Smiraglia D.J., Gao X., Wright F.A., Fruhwald M., et al. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood 97 (2001) 3226-3233
63. International-Human-Genome-Sequencing-Consortium. Finishing the euchromatic sequence of the human genome. Nature 431 (2004) 931-945
64. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295 (2002) 1079-1082
65. Liu S., Shen T., Huynh L., Klisovic M.I., Rush L.J., Ford J.L., et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 65 (2005) 1277-1284
66. Villa R., Pasini D., Gutierrez A., Morey L., Occhionorelli M., Vire E., et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11 (2007) 513-525
67. Villa R., Morey L., Raker V.A., Buschbeck M., Gutierrez A., De Santis F., et al. The methyl-CpG binding protein MBD1 is required for PML-RARalpha function. Proc Natl Acad Sci U S A 103 (2006) 1400-1405
68. Tabe Y., Konopleva M., Kondo Y., Contractor R., Jin L., Ruvolo V., et al. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Ann Hematol 85 (2006) 689-704
69. Ohm J.E., and Baylin S.B. Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation?. Cell Cycle 6 (2007) 1040-1043
70. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39 (2007) 237-242
71. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39 (2007) 232-236
72. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., et al. Epigenetic stem cell signature in cancer. Nat Genet 39 (2007) 157-158
73. Opavsky R., Wang S.H., Trikha P., Raval A., Huang Y., Wu Y.Z., et al. CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet 3 (2007) 1757-1769
74. Krivtsov A.V., and Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7 (2007) 823-833
75. Whitman S.P., Ruppert A.S., Marcucci G., Mrózek K., Paschka P., Langer C., et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 109 (2007) 5164-5167
76. Dorrance A.M., Liu S., Yuan W., Becknell B., Arnoczky K.J., Guimond M., et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest 116 (2006) 2707-2716
77. Whitman S.P., Liu S., Vukosavljevic T., Rush L.J., Yu L., Liu C., et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 106 (2005) 345-352
78. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20 (2002) 2429-2440
79. Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.L., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11 (2005) 3604-3608
80. Fenaux P., Mufti G., Santini V., Finelli C., Giagounidis A., Schoch R., et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. [abstract]. Blood (ASH Annual Meeting Abstracts) 110 (2007) 817
81. Fabre C., Gardin C., Mbida R.-M., Quesnel Q., Dreyfus F., et al. Treatment of AML with azacytidine (AZA): current results of the French ATU program. [abstract]. Blood (ASH Annual Meeting Abstracts) 110 (2007) 1849
82. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006) 1794-1803
83. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 (2007) 52-57
84. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (2004) 1635-1640
85. Yang A.S., Doshi K.D., Choi S.W., Mason J.B., Mannari R.K., Gharybian V., et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66 (2006) 5495-5503
86. Cashen A., Schiller G., Larsen J., Cullen M., and DiPersio J. Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML). [abstract]. Blood (ASH Annual Meeting Abstracts) 108 (2006) 1984
87. Warrell Jr. R.P., He L.Z., Richon V., Calleja E., and Pandolfi P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90 (1998) 1621-1625
88. Warrell Jr. R.P. Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica 84 (1999) 75-77 Suppl EHA-4
89. Gore S.D., Weng L.J., Figg W.D., Zhai S., Donehower R.C., Dover G., et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8 (2002) 963-970
90. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105 (2005) 959-967
91. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2008) 1060-1066
92. Kuendgen A., Strupp C., Aivado M., Bernhardt A., Hildebrandt B., Haas R., et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104 (2004) 1266-1269
93. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109 (2007) 2781-2790
94. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66 (2006) 6361-6369
95. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108 (2006) 3271-3279
96. Soriano A.O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110 (2007) 2302-2308
97. Blum W., Klisovic R.B., Hackanson B., Liu Z., Liu S., Devine H., et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25 (2007) 3884-3891
98. Ravandi F., Faderl S., Deborah Thomas D., Burger J., Koller C., Garcia-Manero G., et al. Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia. [abstract]. Blood (ASH Annual Meeting Abstracts) 110 (2007) 897
99. Garcia-Manero G., Yang A., Klimek V., Cortes J., Ravandi F., Newsome W., et al. Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). [abstract]. Blood (ASH Annual Meeting Abstracts) 110 (2007) 444